Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05057494 · ClinicalTrials.gov registry record · Phase 3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
- 20
- Study locations
NCT05057494 is a Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 607 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05057494, a Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Acalabrutinib
Study Locations (20)
New York
- Research Site - Buffalo
- Research Site - New Hyde Park
- Research Site - New York
- Research Site - Rochester
Washington
- Research Site - Seattle
- Research Site - Seattle
Arizona
- Research Site - Tucson
California
- Research Site - La Jolla
Colorado
- Research Site - Longmont
Florida
- Research Site - Jacksonville
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2029-04-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05057494
The ClinicalTrials.gov registry entry for NCT05057494 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT05057494 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Washington, Arizona.
Frequently Asked Questions
What is clinical trial NCT05057494 about?
NCT05057494 is a clinical study titled "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
What is the current status of trial NCT05057494?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2022-09-12. Estimated completion is 2029-04-10.
What conditions does trial NCT05057494 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05057494?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT05057494?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05057494 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.